HK1244671A1 - 抗基質金屬蛋白酶9的抗體 - Google Patents

抗基質金屬蛋白酶9的抗體

Info

Publication number
HK1244671A1
HK1244671A1 HK18103980.6A HK18103980A HK1244671A1 HK 1244671 A1 HK1244671 A1 HK 1244671A1 HK 18103980 A HK18103980 A HK 18103980A HK 1244671 A1 HK1244671 A1 HK 1244671A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
matrix metalloproteinase
metalloproteinase
matrix
Prior art date
Application number
HK18103980.6A
Other languages
English (en)
Inventor
喬安妮‧I‧亞當肯維克茲
維多莉亞‧史密斯
宗‧蔡
邁克爾‧J‧霍金斯
Original Assignee
吉利德生物製劑公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/027160 external-priority patent/WO2013130078A1/en
Application filed by 吉利德生物製劑公司 filed Critical 吉利德生物製劑公司
Publication of HK1244671A1 publication Critical patent/HK1244671A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18103980.6A 2012-02-29 2015-06-10 抗基質金屬蛋白酶9的抗體 HK1244671A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605181P 2012-02-29 2012-02-29
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9
US201361755444P 2013-01-22 2013-01-22

Publications (1)

Publication Number Publication Date
HK1244671A1 true HK1244671A1 (zh) 2018-08-17

Family

ID=49003113

Family Applications (4)

Application Number Title Priority Date Filing Date
HK18103980.6A HK1244671A1 (zh) 2012-02-29 2015-06-10 抗基質金屬蛋白酶9的抗體
HK15105497.0A HK1204926A1 (zh) 2012-02-29 2015-06-10 抗基質金屬蛋白酶 的抗體
HK15105850.1A HK1204981A1 (zh) 2012-02-29 2015-06-19 抗基質金屬蛋白酶 的抗體
HK18107631.0A HK1248246A1 (zh) 2012-02-29 2015-06-19 抗基質金屬蛋白酶9的抗體

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK15105497.0A HK1204926A1 (zh) 2012-02-29 2015-06-10 抗基質金屬蛋白酶 的抗體
HK15105850.1A HK1204981A1 (zh) 2012-02-29 2015-06-19 抗基質金屬蛋白酶 的抗體
HK18107631.0A HK1248246A1 (zh) 2012-02-29 2015-06-19 抗基質金屬蛋白酶9的抗體

Country Status (23)

Country Link
US (2) US9732156B2 (zh)
EP (2) EP2819697A4 (zh)
JP (3) JP6144286B2 (zh)
KR (1) KR20140130513A (zh)
CN (2) CN107184974A (zh)
AP (1) AP2014007921A0 (zh)
AU (1) AU2013203619B2 (zh)
BR (1) BR112014021081A2 (zh)
CA (1) CA2865501A1 (zh)
CL (1) CL2014002258A1 (zh)
CO (1) CO7061039A2 (zh)
CR (1) CR20140451A (zh)
EA (1) EA201491599A1 (zh)
EC (1) ECSP14020644A (zh)
HK (4) HK1244671A1 (zh)
MD (1) MD20140108A2 (zh)
MX (2) MX2014010447A (zh)
MY (1) MY167236A (zh)
NZ (1) NZ629178A (zh)
PH (1) PH12014501927A1 (zh)
SG (2) SG10201610788VA (zh)
WO (1) WO2013130905A1 (zh)
ZA (1) ZA201406318B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101518144B1 (ko) 2010-08-27 2015-05-28 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
JP2014517279A (ja) 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
SG11201405305PA (en) 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
CA3184564A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2
CA3174012A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
JP6749838B2 (ja) * 2014-01-30 2020-09-02 コヒラス・バイオサイエンシズ・インコーポレイテッド かん流培地
EP3110847A1 (en) * 2014-02-27 2017-01-04 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9 and methods of use thereof
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
TN2017000024A1 (en) 2014-08-19 2018-07-04 Merck Sharp & Dohme Anti-tigit antibodies.
AU2016307845B2 (en) 2015-08-14 2020-10-15 Merck Sharp & Dohme Llc Anti-TIGIT antibodies
US20170174788A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
KR101783907B1 (ko) * 2016-03-15 2017-10-10 다이노나(주) ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물
WO2017177179A1 (en) * 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
TWI676482B (zh) * 2017-03-23 2019-11-11 高雄醫學大學 盤基蛋白結構域受體１的抑制劑及活化劑及其用途
AU2018277256A1 (en) 2017-05-31 2020-01-30 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in Crohn's disease patients
EP3656861A4 (en) 2017-07-18 2021-04-07 Daiichi Sankyo Company, Limited ACTIVE MMP9-BINDING PEPTIDE
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
IL264768A (en) * 2019-02-10 2020-08-31 Sagi Irit ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
US20230074615A1 (en) * 2019-05-21 2023-03-09 The Regents Of The University Of California Mmp-9 antibodies and methods of use thereof
US20230140976A1 (en) * 2020-03-30 2023-05-11 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
WO2023154814A2 (en) * 2022-02-09 2023-08-17 Sera Prognostics, Inc. Shbg and ibp4 antibodies and methods using same
CN114292834B (zh) * 2022-03-09 2022-05-31 天津辅元生物医药科技有限公司 一种融合蛋白酶及其制备方法、其在提取i型胶原蛋白中的应用以及该i型胶原蛋白的用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
DE69412466T2 (de) 1993-11-30 1999-04-29 Fuji Yakuhin Kogyo Kk Neue metalloprotease und kodierende dna dafür
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7101975B1 (en) 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
CA2379373A1 (en) 1999-07-13 2001-01-18 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins
WO2002066057A2 (en) 2001-02-23 2002-08-29 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
SE0102298D0 (sv) 2001-06-27 2001-06-27 Astrazeneca Ab Crystal structure of enzyme and uses thereof
WO2003006006A1 (en) 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
WO2003044058A2 (en) 2001-11-23 2003-05-30 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
AU2003270330B2 (en) 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
WO2004076614A2 (de) 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
US7524938B2 (en) 2003-04-04 2009-04-28 Yeda Research And Development Co., Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
CA2550551C (en) * 2004-01-16 2013-10-29 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2006037513A1 (en) 2004-10-09 2006-04-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
US20070003981A1 (en) 2005-06-29 2007-01-04 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of acute coronary syndrome
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
CN101370832B (zh) * 2005-12-02 2014-07-02 健泰科生物技术公司 结合多肽及其用途
WO2007144781A2 (en) 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Diagnostic methods and kits utilizing antibodies for metalloproteases
WO2008088864A2 (en) 2007-01-18 2008-07-24 The Trustess Of Columbia University In The City Of New York Matrix metalloproteinase-9-related methods
JP5513130B2 (ja) 2007-02-23 2014-06-04 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 金属タンパク質の活性を阻害するために有用な抗体および該抗体を含有する医薬組成物
AR066913A1 (es) * 2007-06-08 2009-09-23 Irm Llc Metodos y composiciones para inducir la apoptosis en celulas cancerosas
CN105330743B (zh) 2007-08-02 2019-05-28 吉利德生物制剂公司 Lox和loxl2抑制剂及其应用
CN102083455B (zh) 2007-08-15 2015-01-07 耶达研究及发展有限公司 Mmp-9的调节剂及其用途
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
CA2717803A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
CA2717576A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 binding proteins
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
AU2009308369A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
WO2010059543A1 (en) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
DE102009030321A1 (de) * 2009-06-24 2011-01-05 Siemens Aktiengesellschaft Verfahren zur Abbildung von Tumorgewebe
CN102822202B (zh) 2010-01-27 2015-07-22 耶达研究及发展有限公司 抑制金属蛋白的抗体
WO2011097513A1 (en) 2010-02-04 2011-08-11 Gilead Biologics, Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
US8896483B2 (en) * 2010-07-15 2014-11-25 Evgeny Markin Method of automatic target angle tracking by monopulse radar under conditions of interference distorting location characteristic
KR101518144B1 (ko) 2010-08-27 2015-05-28 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
SG11201405305PA (en) 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
EP2819697A4 (en) 2016-03-09
MX2018007630A (es) 2023-04-12
EP3255063A3 (en) 2018-02-07
EP3255063A2 (en) 2017-12-13
US20180002446A1 (en) 2018-01-04
CN104271156A (zh) 2015-01-07
EP2819697A1 (en) 2015-01-07
KR20140130513A (ko) 2014-11-10
HK1204981A1 (zh) 2015-12-11
BR112014021081A2 (pt) 2017-07-04
ECSP14020644A (es) 2015-09-30
CO7061039A2 (es) 2014-09-19
SG10201610788VA (en) 2017-03-30
JP6343368B2 (ja) 2018-06-13
US20130224210A1 (en) 2013-08-29
AU2013203619A1 (en) 2013-09-19
JP2018150343A (ja) 2018-09-27
CN104271156B (zh) 2017-06-16
ZA201406318B (en) 2016-07-27
NZ629178A (en) 2016-09-30
MD20140108A2 (ro) 2015-03-31
JP2017178952A (ja) 2017-10-05
CA2865501A1 (en) 2013-09-06
HK1204926A1 (zh) 2015-12-11
CL2014002258A1 (es) 2015-02-20
JP2015509959A (ja) 2015-04-02
AP2014007921A0 (en) 2014-09-30
HK1248246A1 (zh) 2018-10-12
MX2014010447A (es) 2015-06-23
US9732156B2 (en) 2017-08-15
JP6144286B2 (ja) 2017-06-07
CN107184974A (zh) 2017-09-22
EA201491599A1 (ru) 2015-05-29
WO2013130905A1 (en) 2013-09-06
PH12014501927A1 (en) 2014-11-24
AU2013203619B2 (en) 2015-02-26
MY167236A (en) 2018-08-14
CR20140451A (es) 2014-11-17
SG11201405273YA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
IL255300A0 (en) Antibodies to matrix metalloproteinase 9 (mmp9)
HK1248246A1 (zh) 抗基質金屬蛋白酶9的抗體
ZA201406319B (en) Antibodies to matrix metalloproteinase 9
EP2832855A4 (en) NEW ANTI-SIGLEC ANTIBODY-15
ZA201408213B (en) Anti-transglutaminase 2 antibodies
EP2863742A4 (en) MICROCAPSULE
EP2856158A4 (en) PROCEDURE RELATED TO RITUXIMAB
EP2927243A4 (en) ANTI-VASOHIBIN ANTIBODY-2
GB2507762B (en) Improvements to dartboards
SG10201700568RA (en) Antibodies to matrix metalloproteinase 9